We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intercontinental Exchanges (ICE) March Volume Improves Y/Y
Read MoreHide Full Article
Intercontinental Exchange, Inc.’s (ICE - Free Report) average daily volume (ADV) in March increased 56% to 9.4 million largely backed by improved Financial ADV, Commodities ADV and Energy ADV. The company reported 38.5% year-over-year increase in Financials volume that rose to 4.4 million contracts per day. There were 22 trading days in March.
Agriculture and Metals ADV of 0.6 million contracts increased 38.6%. Energy volume too increased about 82.2% to 4.4 million contracts per day. Thus, Commodities ADV increased nearly 75.9% to 4.9 million in March.
Interest rate volume increased 32.3% to 3.4 million contracts per day whereas Equity Index volume increased 63.1% to 1 million contracts. Foreign exchange volume was up 55.9% to nearly 0.05 million contracts.
Q1 Volumes
Intercontinental Exchange’s first-quarter futures & options ADV increased 42% year over year to 8 million.
Energy ADV surged 54% year over year to 3.9 million and agriculture & metals ADV increased 31% year over year to 0.6 million.
Interest rate ADV was up 28% year over year to 2.9 million. Equity indices ADV rose 47% year over year.
Shares of Intercontinental Exchange have underperformed the industry in a year’s time. The stock has gained 5.2%, underperforming the industry’s increase of 7%. Nevertheless, the company’s product portfolio, along with a broad range of risk management services, strategic buyouts and a robust capital position will likely help the stock retain its growth momentum.
Recently, securities exchanges, namely CME Group Inc. (CME - Free Report) and MarketAxess Holdings Ltd. (MKTX - Free Report) and Cboe Global Markets, Inc. (CBOE - Free Report) also posted their respective monthly volumes.
CME Group’s ADV increased 68% year over year in March as volumes increased across all the six product lines. MarketAxess reported trading volume of $916.6 billion for March. It consists of $269.5 billion in credit volume and $647.1 billion in rates volume. Cboe Global reported strong ADV for March 2019. Total ADV of 12 million contracts declined 68% year over year due to strong performance across the business lines — Options, Futures, U.S. Equities and European Equities.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Intercontinental Exchanges (ICE) March Volume Improves Y/Y
Intercontinental Exchange, Inc.’s (ICE - Free Report) average daily volume (ADV) in March increased 56% to 9.4 million largely backed by improved Financial ADV, Commodities ADV and Energy ADV. The company reported 38.5% year-over-year increase in Financials volume that rose to 4.4 million contracts per day. There were 22 trading days in March.
Agriculture and Metals ADV of 0.6 million contracts increased 38.6%. Energy volume too increased about 82.2% to 4.4 million contracts per day. Thus, Commodities ADV increased nearly 75.9% to 4.9 million in March.
Interest rate volume increased 32.3% to 3.4 million contracts per day whereas Equity Index volume increased 63.1% to 1 million contracts. Foreign exchange volume was up 55.9% to nearly 0.05 million contracts.
Q1 Volumes
Intercontinental Exchange’s first-quarter futures & options ADV increased 42% year over year to 8 million.
Energy ADV surged 54% year over year to 3.9 million and agriculture & metals ADV increased 31% year over year to 0.6 million.
Interest rate ADV was up 28% year over year to 2.9 million. Equity indices ADV rose 47% year over year.
Shares of Intercontinental Exchange have underperformed the industry in a year’s time. The stock has gained 5.2%, underperforming the industry’s increase of 7%. Nevertheless, the company’s product portfolio, along with a broad range of risk management services, strategic buyouts and a robust capital position will likely help the stock retain its growth momentum.
Intercontinental Exchange currently carries Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Recently, securities exchanges, namely CME Group Inc. (CME - Free Report) and MarketAxess Holdings Ltd. (MKTX - Free Report) and Cboe Global Markets, Inc. (CBOE - Free Report) also posted their respective monthly volumes.
CME Group’s ADV increased 68% year over year in March as volumes increased across all the six product lines. MarketAxess reported trading volume of $916.6 billion for March. It consists of $269.5 billion in credit volume and $647.1 billion in rates volume. Cboe Global reported strong ADV for March 2019. Total ADV of 12 million contracts declined 68% year over year due to strong performance across the business lines — Options, Futures, U.S. Equities and European Equities.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>